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Activated  macrophages  are  well  known  to  exhibit  anti-tumor  properties.  However,  certain  cell  types
show  intrinsic  resistance.  Searching  for a mechanism  that  could  explain  this  phenomenon,  we observed
that  the  supernatant  of resistant  cells  could  confer  resistance  to otherwise  sensitive  tumor  cells,  sug-
gesting  the presence  of a secreted  suppressor  factor.  The  effect  was  abolished  upon  dialysis,  indicating
that  the suppressor  factor  has  a low  molecular  weight.  Further  studies  showed  that  prostaglandin  E2
(PGE2) is secreted  by the  resistant  tumor  cells and  that  inhibition  of  PGE2 production  by indomethacin,ndomethacin
GE2
umor cell resistance
acrophage cytotoxicity
NF
a cyclooxygenase  (COX)  inhibitor,  eliminated  the  macrophage  suppression  factor  from  the  supernatant,
and  sensitized  the  resistant  tumor  cells  to  macrophage  cytotoxicity.  This  study  emphasizes  the important
role  of  tumor-secreted  PGE2 in escaping  macrophage  surveillance  and  justiﬁes  the use of  COX  inhibitors
as  an  adjuvant  for improving  tumor  immunotherapy.
©  2016  The  Authors.  Published  by Elsevier  B.V.  on behalf  of  European  Federation  of Immunological
Societies. This  is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/. Introduction
Activated macrophages have the propensity to kill tumor cells
oth in vitro and in vivo in virtue of their ability to produce
umor necrosis factor- (TNF), tumor necrosis factor-related
poptosis-inducing ligand (TRAIL), and nitric oxide [1–3]. Usually
he macrophages need to be activated in order to kill tumor cells.
n exception is the ability of macrophages to eliminate teratocar-
inoma cells and embryonic stem cells without the need for an
xternal activation signal [4]. Several activation agents can increase
he tumoricidal activity of macrophages, including the cytokines
FN, IL-12 and TNF, whole bacteria such as Mycobacterium bovis
acille Calmette-Guérin (BCG) and mycoplasma, and bacterial and
east components such as lipopolysaccharide (LPS), zymosan and
-glucans [2,5–7].
The tumor microenvironment is comprised of a variety of non-
alignant cells such as ﬁbroblasts, stromal cells, endothelial cells,
Abbreviations: COX, cyclooxygenase; PGE2, prostaglandin E2; M,
acrophages; NSAID, non-steroid anti-inﬂammatory drugs; TNF, tumor necrosis
actor .
∗ Corresponding author.
E-mail addresses: totaryjainh@health.usf.edu (H. Totary-Jain),
onit.sionov@mail.huji.ac.il (R.V. Sionov), ruthg@ekmd.huji.ac.il (R. Gallily).
ttp://dx.doi.org/10.1016/j.imlet.2016.05.011
165-2478/© 2016 The Authors. Published by Elsevier B.V. on behalf of European Federatio
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pericytes and a variety of immune cells that can make up to 90% of
the total tumor volume [8]. Within the tumor microenvironment,
the macrophages are exposed to a wide range of tumor-secreted
factors as well as cytokines and chemokines secreted by immune
cells, which modulate macrophage functions. Among these factors,
TGF has drawn much attention, being produced by the stimulated
macrophages themselves and various tumor cells. TGF promotes
macrophage polarization from an anti-tumor M1 to a pro-tumor
M2 phenotype [9,10]. Other factors that can contribute to this
polarization are the cytokines IL-4, IL-13 and IL-10 [10,11] and
repeated activation of macrophages, which leads to loss of TNF
secretion and acquisition of high iNOS activity (our unpublished
data). Indeed, the central macrophage product TNF promotes
the generation of immature myeloid-derived suppressor cells
(MDSCs) [12], providing a negative feedback mechanism to tune
the immune response. Alternatively activated M2 macrophages
have a strikingly different gene expression proﬁle compared with
M1 macrophages and express a different combination of surface
receptors (e.g., CD163), cytokines (e.g., IL-10), tumor growth factors
(e.g., EGF, FGF1, TGF1), pro-angiogenic factors (e.g., VEGF), matrix
remodeling factors (e.g., ﬁbrin and matrix metallopeptidases) and
chemokines (e.g., CCL17/TARC, CCL22/MDC and CCL24/Eotaxin-
2) [10,11]. In addition, M2  macrophages produce lower levels of
ROS, but express higher levels of arginase I and indoleamine 2,3-
dioxygenase (IDO) [10,11]. Additional subtypes of macrophages
n of Immunological Societies. This is an open access article under the CC BY-NC-ND
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ave also been identiﬁed [13], suggesting a broad spectrum of
acrophage activation stages [6].
We  have observed that while some tumor cells are susceptible
o macrophage cytotoxicity, others are resistant. The aim of our
tudy was to characterize the mechanisms involved in conferring
acrophage resistance upon tumor cells. This study shows that a
ow molecular weight factor secreted by tumor cells, deﬁned as
rostaglandin E2 (PGE2), prevents macrophage activation required
or tumor cytotoxicity. Inhibition of PGE2 production, using the
on-steroid anti-inﬂammatory drug (NSAID) indomethacin, not
nly restored macrophage activation, but also conferred sensitivity
f the otherwise resistant tumor cells to macrophage cytotoxicity.
. Material and methods
.1. Mice
C57BL/6 mice were obtained from the Animal Breeding Farm,
ebrew University-Hadassah Medical School of Jerusalem. All
xperiments involving animals were approved by the Hebrew Uni-
ersity’s Institutional Animal Care and Use Committee.
.2. Cell cultures
Bone-marrow-derived macrophages (BMM)  were obtained
rom bone marrow cells (usually ∼30 × 106 cells per mouse)
arvested from the femur and tibia of 6–8-week old female
57BL/6 mice, which were cultivated in DMEM supplemented with
5% heat-inactivated fetal calf serum (FCS), 5% heat-inactivated
orse serum, 30% L929 cell conditioned medium (LCM), 2 mM
-glutamine, 10 mM HEPES, 100 U/ml penicillin and 100 g/ml
treptomycin. The macrophages were cultivated on 9 cm diameter
acteriological grade culture dishes (Miniplast, Ein Shemer, Israel)
nd were used as effectors 10–21 days after bone marrow seeding.
CM was prepared by seeding 106 L929 cells in 20 ml DMEM sup-
lemented with 10% FCS in a 75 cm2 tissue culture ﬂask (Nunclon,
enmark). Following 4–5 days incubation, when a monolayer had
een reached, the supernatant was collected and sterile ﬁltered.
A9 ﬁbrosarcoma cells (a C3H ﬁbrosarcoma derived from
929 cells), L929 ﬁbrosarcoma cells, NIH3T3 mouse embryonic
broblast-like cells and M109 Madison lung carcinoma cells were
rown in DMEM supplemented with 5% heat-inactivated FCS, 2 mM
-glutamine, 10 mM  HEPES and antibiotics. The FCS used was
elected from batches that did not pre-activate macrophages. All
ell cultures were incubated at 37◦C in a humidiﬁed incubator
ontaining 5% CO2. All cultures were routinely tested for being
ycoplasma-free.
.3. Cytotoxicity assay
Cytotoxicity assay was performed as described previously [4].
rieﬂy, target cells in the log phase of growth were pulsed with
 Ci/ml of [3H]thymidine (sp. Act 5 Ci/mM;  American Radiola-
eled Chemicals, Inc.) for 24 h, washed in PBS, trypsinized and
esuspended in DMEM with 10% FCS, 2 mM l-glutamine, and 10 mM
EPES. Ten thousand target cells were added to 1 × 105 BMM
n 96 ﬂat-bottomed microwells (Nunc, Denmark) in 300 l DMEM
upplemented with 10% heat-inactivated FCS in the absence or
resence of 1 g/ml LPS (Escherichia coli o55:B5, Bacto®, Difco). Fol-
owing 72 h, the supernatants (300 l) were harvested from the
icrowells, diluted with Insta-Gel (Packard, Downers Grove, Illi-
ois) and the radioactivity counted. The samples were kept at 4◦C
or 24 h prior to counting. Percentage speciﬁc cytolysis was calcu-
ated by the following formula: % Cytolysis = [(E-SR)/(T-SR)] × 100%
here E is the d.p.m. of the supernatant from co-culture of target
ells and macrophages, SR the spontaneous release in d.p.m. of any Letters 176 (2016) 1–7
equal number of target cells in medium without macrophages, and
T the total d.p.m. uptake of target cells.
For determination of target cell sensitivity to TNF, 5000
[3H]thymidine-labeled cells were seeded in 100 l DMEM with 5%
FCS in each well of a 96-well plate. At the following day, 50 l of var-
ious concentrations of TNF (Genentech Inc., San Francisco) were
added, followed by a 3-day incubation at 37◦C. The extent of cell
death was determined by measuring the released radioactivity as
described above. Control wells got 50 l of medium. Alternatively,
cells were incubated with TNF in the presence of 2 g/ml Acti-
nomycin D (Sigma), and the extent of cell death determined 18 h
later.
2.4. Production of TNF  ˛ by activated macrophages and
determination of TNF  ˛ titer
One hundred thousand BMM were added to each of the 96 ﬂat-
bottomed microwells in 100 l DMEM with 10% heat-inactivated
FCS, 18 h prior to activation. The activation step was performed by
changing the medium to DMEM without FCS or cell culture super-
natant in the same medium, either in the absence or presence of
1 g/ml LPS, followed by incubation for 24 h. Macrophage super-
natants were assayed for TNF by bioassay as described previously
[4]. Brieﬂy, 4 × 104 Cl-7 cells were plated per 96 ﬂat-bottomed
microwell in 100 l DMEM with 5% FCS. On the following day, 3-
fold dilutions of test supernatants and control media were made
in the wells, followed by immediate addition of actinomycin D
(Sigma; 2 g/ml, ﬁnal concentration). The cultures were incubated
for 20 h at 37◦C, and the survived Cl-7 cells were stained for 10 min
with crystal violet (0.2% in 2% ethanol), washed with running tap
water and allowed to dry. The destruction of the Cl-7 monolayer
was determined by the amount of light (at 550 nm) absorbed by
the residual stained cells in the wells using a Dynatech MicroElisa
Reader (Artek, Farmingdale, NY). The S50 titer of TNF was  deﬁned
as the reciprocal of the dilution of the test solution required to
destroy 50% of the target cell monolayer, as compared to control
samples.
2.5. Conditioned medium of cultured cells
2 × 105 cells were seeded per well in a 24-well culture plate
(Nunclon, Denmark) in 1.5 ml  DMEM with 5% FCS. After 24 h, the
medium was exchanged to fresh medium, and the supernatant col-
lected 24 h later. The supernatants were centrifuged at 1200 rpm for
15 min, and kept at 4◦C until use.
2.6. Surface TNF  ˛ receptor binding assay
The assay was performed in accordance to Holtmann & Wallach
[14]. TNF was labeled with 125I by the chloramine-T method to
a speciﬁc radioactivity of 1500 Ci/mmol. One million target cells
were seeded in growth medium in tissue culture plates the day
before assay. On the following day, the cells were washes and
incubated on ice for 2 h with 0.5 nM 125I-TNF in the absence
or presence of excess unlabeled TNF (20 M) in PBS containing
140 mM NaCl, 1.5 mM KH2PO4, 8 mM Na2HPO4, 2.7 mM KCl, 0.5 mM
MgCl2, 0.9 mM CaCl2, 0.5% bovine serum albumin (BSA) and 15 mM
sodium azide. Thereafter, the cells were washed three times in the
binding buffer, detached in Ca2+- and Mg2+-free PBS containing
5 mM EDTA and transferred to vials for radioactivity measure-
ments. Speciﬁc binding of TNF was calculated by subtracting the
values of binding observed in the presence of an excess of unlabeled
TNF from the value of binding observed with 127I-TNF  alone.
H. Totary-Jain et al. / Immunology Letters 176 (2016) 1–7 3
Table  1
Binding of 125I-TNF to the different cell lines. The numbers represents the amount
of  radioactive TNF bound to 1 × 106 cells after subtraction of the non-speciﬁc
radioactive binding observed in the presence of excess unlabeled TNF. The input
125I-TNF was  2 × 105 cpm.
Cell lines Speciﬁc binding (cpm)
NIH3T3 10,427
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Table 2
Production of PGE2 by NIH3T3 and M109 cells. The PGE2 concentrations in the
conditioned medium (CM) of the indicated cell lines was  determined by radioim-
munoassay as described in the Section 2.7. Conditioned media were collected 24 h
after seeding 2 × 105 cells in 1.5 ml DMEM with 5% FCS in a 24-well culture plate.
MEF: mouse embryonic ﬁbroblasts. n.d.: non detectable.
Cell lines PGE2 conc in CM
NIH3T3 502 pg/ml (1.4 nM)
M109 397 pg/ml (1.1 nM)M109 12,778
L929 4045
.7. Determination of prostaglandin E2 (PGE2) concentration
The PGE2 concentrations in cell supernatants were deter-
ined by radioimmunoassay. 100 l of sample, buffer alone or
GE2 standard (0.15–10 ng/ml; Sigma) were mixed with 100 l
.01 M sodium phosphate buffer pH 7.4 containing 0.15 M NaCl,
.1% BSA, 0.1% NaN3 and 500 l anti-serum to PGE2 (Bio-Makor;
iluted 1:10). Following a 30 min  incubation at 4◦C, 100 l of
5,6,8,11,12,14,15-3H(N)]-PGE2 (0.1mCi/ml, Amersham, England)
as added at a dilution giving 50,000–100,000 d.p.m. After 60 min
ncubation at 4◦C, 200 l of a dextran coated charcoal solution
1% charcoal with 0.1% dextran (MW  35,000–45,000; Sigma)] in
odium phosphate buffer were added, except for samples intended
or total radioactive read. After vigorous mixing, the samples
ere incubated for 10 min  at 4◦C, followed by centrifugation at
000 rpm for 15 min  at 4◦C. 250 l of the supernatant was  mixed
ith 3 ml  of Insta-gel, and the radioactivity was measured in a
-counter. No antibody was added to the blank samples. The per-
entage of bound radioactive PGE2 was calculated according to
(S − B)/(T − B)] × 100%, where S is the d.p.m of the sample, B the
.p.m of the blank sample and T the total radioactive amount. The
imitation of this assay was 5 pg/ml PGE2.
.8. Statistical analysis
Experiments were repeated 3–5 times. The arithmetic average
f all experiments performed is given. Statistical signiﬁcance was
ssessed by the one-tail distribution-free Mann-Whitney U test.
rror bars represent standard error. Differences were considered
igniﬁcant when the p value was 0.05 or less.
. Results
.1. Differential sensitivity of transformed cells to macrophage
ytotoxicity
The aim of this study was to understand why some transformed
ells are resistant to macrophage-mediated killing. We  observed
hat M109 lung carcinoma cells and NIH3T3 ﬁbroblast-like cells
ere relatively resistant, whereas A9 and L929 ﬁbroblast-like cells
ere highly sensitive to killing by activated macrophages (Fig. 1A).
one of these cells were killed by non-activated macrophages, as
xpected. The resistance could be due to intrinsic resistance to
NF-mediated killing, the major mediator of macrophage cyto-
oxicity, or the secretion of a macrophage suppressor factor by the
umor cells. We  ﬁrst analyzed whether the NIH3T3 and M109 cells
xpress TNF receptors by using the TNF binding assay [14]. We
ound that NIH3T3 and M109 bound even more 127I TNF per cell
han the macrophage-sensitive L929 cells (Table 1), thus exclud-
ng the lack of TNF receptors as the reason for their resistance
o macrophage cytotoxicity. It could be that the cells are resis-
ant to the cytotoxic effect of TNF. To test this possibility, the
ells were incubated in various dilutions of activated macrophage-
onditioned medium, which contained an active TNF S50 titer of
9,170 when analyzed on Cl-7 cells in the presence of actinomycinA9 n.d.
MEF  185 pg/ml (0.5 nM)
D. This assay shows that both NIH3T3 and M109 responded to the
macrophage-conditioned medium by cell death (Fig. 1B).
We next studied whether the resistant tumors secrete a
factor that prevents macrophage activation. For this purpose,
macrophages were incubated with the conditioned medium of the
transformed cells in the absence or presence of 1 g/ml LPS, and
following a 24 h-incubation at 37◦C, the amount of TNF secreted
by the macrophages was  determined. We  observed that, while
the conditioned medium of A9 cells did not interfere with the
macrophages’ ability to secrete TNF in response to LPS, the condi-
tioned media of NIH3T3 and M109 cells almost completely blocked
TNF secretion by macrophages (90–98% inhibition; Fig. 1C).
These data suggest that the transformed cells indeed secrete a
macrophage inhibitory factor.
In order to study whether the inhibitory factor has a low or
high molecular weight, we  dialyzed the cell conditioned media or
control medium against PBS for 48 h and then against DMEM to
restore essential nutrients using a dialysis tube with an MW cut-
off of 10,000 Da. The dialyzed conditioned media were analyzed for
their effects on LPS-induced TNF secretion by macrophages. After
dialysis, the conditioned media of NIH3T3 and M109 had lost their
ability to inhibit TNF secretion, and they even enhanced its pro-
duction (Fig. 1D). This indicates the presence of a low molecular
weight inhibitory factor in the conditioned media.
3.2. Identiﬁcation of PGE2 as the macrophage inhibitory factor
Since it has been reported that the low-molecular weight bio-
chemical compound prostaglandin E2 (PGE2) can inhibit TNF
secretion from macrophages [15], we  wondered whether our
inhibitory factor is PGE2. We  ﬁrst analyzed the presence of PGE2 in
the conditioned media, and observed that both NIH3T3 and M109
cells produced high levels of PGE2, while PGE2 couldn’t be detected
in the conditioned media of A9 cells (Table 2). We then analyzed
the effect of various concentrations of PGE2 on TNF secretion by
macrophages, and surprisingly observed a dose-dependent effect
where high PGE2 concentrations (from 1 nM–1 M)  strongly inhib-
ited TNF secretion, while low concentrations (especially at 0.1–1
pM)  strongly enhanced it (Fig. 2A). The synergistic effect of low
PGE2 concentrations on TNF secretion might explain why  the
dialyzed conditioned medium even enhanced its secretion by LPS-
stimulated macrophages (Fig. 1D). In order to validate that the
PGE2 secreted from NIH3T3 and M109 is the factor that inhibited
macrophage activation, the cells were treated with the cyclooxyge-
nase (COX) inhibitor indomethacin, and the resulting conditioned
medium was analyzed for their ability to affect TNF production.
Indeed, indomethacin abolished the macrophage inhibitory effect
of the conditioned medium and even enhanced TNF secretion
(Fig. 2B). The PGE2 concentration in the conditioned medium was
negligible in the presence of indomethacin (undetectable in the
NIH3T3 conditioned media, while 10 ng/ml in the M109 condi-
tioned media). In light of these encouraging data, it was  intriguing
to determine whether indomethacin could sensitize the resistant
cells to macrophage cytotoxicity. For this purpose, NIH3T3, M109
4 H. Totary-Jain et al. / Immunology Letters 176 (2016) 1–7
Fig. 1. (A) The sensitivity of various transformed cells to activated macrophage cytotoxicity. 1 × 104 target cells were incubated with 1 × 105 BMM in the presence of
1  g/ml LPS for 3 days. In the absence of LPS, there was  no killing of any cells. p < 0.05 for M109/NIH3T3 versus A9/L929. (B) Cell sensitivity to TNF. NIH3T3, M109 and A9
cells  were incubated in various dilutions of activated macrophage-conditioned medium (BMM-CM) in the presence of 2 g/ml actinomycin D, and the extent of cell death
determined 18 h later. (C) Inhibition of TNF secretion by the conditioned media of transformed cells. One hundred thousand macrophages were incubated in serum-free
medium or in conditioned media (CM) collected from NIH3T3, M109 or A9 cells, in the absence or presence of 1 g/ml LPS for 24 h, and the amount of active TNF secreted
was  determined as described in the Section 2.4. The relative TNF secretion by macrophages in the presence of conditioned medium is presented in comparison to control
medium. p < 0.05 for M109 CM and NIH3T3 CM versus control medium and A9 CM. (D) The suppressor factor is lost upon dialysis of the conditioned media. Conditioned
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tedia were dialyzed for 48 h against PBS, and then against DMEM,  using a dialys
n  LPS-induced TNF secretion by macrophages was analyzed. The data are presen
edium in comparison to dialyzed control medium. p < 0.05 for NIH3T3 dCM and M
nd A9 cells were incubated with macrophages with LPS in the
bsence or presence of 50 M indomethacin, and the extent of
ell killing was measured after 3 days of co-cultivation. Indeed,
ndomethacin sensitized the resistant tumor cells to macrophage
ytotoxicity (Fig. 2C). Further studies showed that when the
acrophage-sensitive A9 cells were incubated with macrophages
hat have been pre-incubated with the resistant NIH3T3 or M109
ells, the cell killing was reduced by 75% (Fig. 2D). This reduction
n cell killing could be reversed by treating the co-cultures with
ndomethacin (Fig. 2D), further emphasizing the central role of
GE2 in mediating the macrophage inhibitory effect. This is fur-
her manifested by the suppression of A9 cell killing when PGE2
as added to the co-culture of A9 and macrophages (Fig. 2E). Max-
mum inhibition was obtained at 1–10 nM PGE2 (47–51% inhibition;
ig. 2E).
. Discussion
Our pioneering study, performed in the late 1980′s, is fully rel-
vant today in light of the current recognition that PGE2 is a key
layer in the carcinogenesis of colon cancer and several other can-
er cell types [16–19], along with the introduction of aspirin in
he clinics for the prevention of colon cancer [20,21]. During the
ears, it has been repeatedly shown that PGE2 suppresses diverse
acrophage functions [22–26] and may  even promote the shift
owards the M2  phenotype [27–30] as well as the appearance ofe with a cut-off of 10,000 Da. The effect of the dialyzed conditioned media (dCM)
s relative TNF secretion by macrophages in the presence of dialyzed conditioned
CM versus dialyzed control medium.
myeloid-derived suppressor cells with tumor-promoting function
[31]. Other studies have demonstrated PGE2 production by vari-
ous cancer cells [27,32,33,34–36], besides being produced by the
macrophages themselves [37,38]. Our study combines these two
issues showing that tumor-secreted PGE2 protects the tumor cells
from macrophage cytotoxicity, a tumor immune escape mechanism
that can be overcome by the drug indomethacin. Indomethacin and
aspirin belong to the same group of non-steroid anti-inﬂammatory
drugs (NSAIDs), and their beneﬁts as adjuvants in cancer therapy
seem thus to be of a dual nature. Namely, by preventing PGE2
production in the tumor cells, these drugs may  directly inhibit
PGE2-dependent tumor cell growth, and, simultaneously, increase
macrophage cytotoxicity towards the tumor cells (Fig. 3). Both
mechanisms contribute to the reduction of the tumor cell mass.
Our study suggests a mechanistic explanation for the anti-tumor
effects observed for indomethacin in various tumor models (e.g.,
[39–41]).
The dose-dependent effects of PGE2 observed by us on
macrophage secretion of TNF has also been observed by another
research group [42]. That group observed that the differential
effects of PGE2 are mediated by changes in the intracellular
cAMP/cGMP ratio [42]. A dose-dependent effect of PGE2 on
macrophage adhesion and migration has also recently been doc-
umented [43]. An interesting fact is that reducing the PGE2 level by
indomethacin may not only prevent the inhibitory effect of PGE2
on macrophages, but may  even lead to such low levels that the
H. Totary-Jain et al. / Immunology Letters 176 (2016) 1–7 5
Fig. 2. (A) Effect of PGE2 on TNF secretion by LPS-stimulated macrophages. Hundred thousand macrophages that have been seeded in each well of a 96-ﬂat bottomed
tissue  culture plate, were exposed to 1 g/ml LPS in the absence or presence of various concentrations of PGE2 as indicated. The amount of TNF secreted was analyzed
24  h later. 1 nM corresponds to 352.4 ng/ml PGE2. p < 0.05 for 1 nM–1 M and 0.1–1 pM PGE2 versus control medium. (B) Indomethacin treatment of NIH3T3 and M109
cells  abolished the macrophage inhibitory effect of conditioned medium. Hundred thousand macrophages were incubated in control medium or conditioned media from
untreated or indomethacin (50 M,  24 h)-treated M109, NIH3T3 and A9 cells in the presence of 1 g/ml LPS, and the amount of TNF secreted was determined 24 h later.
The  data are presented as relative TNF secretion by macrophages under each treatment condition in comparison to that of control medium. p < 0.05 for NIH3T3 CM and
M109  CM in the absence of indomethacin versus control and A9 CM;  and p < 0.05 for NIH3T3 CM and M109 CM in the presence versus in the absence of indomethacin. (C)
Indomethacin sensitized the resistant tumor cells to macrophage cytotoxicity. NIH3T3, M109 and A9 cells were incubated with macrophages in the presence of 1 g/ml LPS
with  or without 50 M indomethacin for 3 days, and the extent of tumor cell killing determined. p < 0.05 for cells in the presence versus in the absence of indomethacin. (D)
The  presence of resistant cells prevented macrophage cytotoxicity on sensitive cells that could be reversed by indomethacin. Five thousand [3H]-thymidine-labeled A9* cells
were  added to 1 × 105 macrophages that have been pre-incubated with 5 × 103 unlabeled NIH3T3, M109 or A9 cells for 24 h. The extent of A9 cell killing was determined after
3 nce of
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b days co-incubation. p < 0.05 for killing of A9 cells in the presence versus in the abse
GE2 was added at 10 pM,  100 pM,  1 nM and 10 nM to the co-culture of A9 cells an
 days later. p < 0.05 for cell killing in the presence versus in the absence of PGE2.umoricidal effect of macrophages is enhanced. Indomethacin even
ncreased the tumoricidal effect of activated macrophages on A9
ells that barely produce PGE2 (Fig. 2C). This might be due to inhi-
ition of PGE2 production by the macrophages themselves during indomethacin. (E) PGE2 suppressed macrophage-mediated cytotoxicity of A9 cells.
rophages in the presence of 1 g/ml LPS, and the extent of cell killing determinedco-cultivation, where the negative feedback mechanism triggered
upon macrophage activation is interrupted.
Of note, we  could only reach up to 50% inhibition of A9 cell killing
by macrophages when adding PGE2, even though the higher con-
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[ig. 3. The Tumor-PGE2-Macrophage Cross-Talk. Tumor cells produce PGE2 that is s
acrophage activation required for anti-tumor function. Interruption of this cross-
imit  tumor growth.
entration (10 nM)  completely blocked TNF secretion. This might
e due to the induction of another tumoricidal factor, such as the
itric oxide radical by PGE2 [44]. Nitric oxide has been shown to
e involved in macrophage killing of L929 ﬁbrosarcoma cells [3].
his scenario might also explain how PGE2 can induce tumorici-
al activity of resident macrophages on L929 cells in the absence
f any other activation signal [45]. Thus, PGE2 may  support some
nti-tumor macrophage activities despite abolishing TNF produc-
ion. This duality of PGE2 action might be important for maintaining
ssential macrophage functions under conditions where excessive
mmune responses are suppressed.
Altogether, our study sheds new light on the tumor cell-
acrophage interrelationship, where macrophage tumoricidal
ctivity can be regained by preventing excessive PGE2 production
sing the NSAID drug indomethacin. Tumor-secreted PGE2 likely
cts in concert with other immune suppressive factors such as TGF
9], based on the observation that indomethacin couldn’t reverse
acrophage killing of A9 cells when co-cultured in the presence of
esistant transformed cells to a level similar to that observed in their
bsence (Fig. 2D). Our data would therefore suggest a potential use
f indomethacin as an adjuvant agent in cancer immunotherapy
hat ought to be combined, for instance, with a TGF inhibitor.
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